The Shifting Landscape for Lung Cancer: Past, Present, and Future

Since that report, smoking rates in the United States have declined significantly, from a peak prevalence of 42% to approximately 15% of adults reporting daily cigarette use in 2015. Risk factors for never-smoker lung cancer include exposure to radon, environmental tobacco smoke, and other indoor ai...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2017-05, Vol.195 (9), p.1150
Main Authors: Vachani, Anil, Sequist, Lecia V, Spira, Avrum
Format: Article
Language:English
Subjects:
Cancer therapies
Cigarettes
Colleges & universities
Disease prevention
Epidemiology
Immunotherapy
Lung cancer
Medicine
Mens health
Monoclonal antibodies
Public health
Risk factors
Smoking cessation
Targeted cancer therapy
Tobacco
Womens health
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since that report, smoking rates in the United States have declined significantly, from a peak prevalence of 42% to approximately 15% of adults reporting daily cigarette use in 2015. Risk factors for never-smoker lung cancer include exposure to radon, environmental tobacco smoke, and other indoor air pollutants; however, a significant fraction of lung cancers occurring in never smokers cannot be definitively associated with established environmental risk factors. Unlike the rapid reduction in cardiovascular risk after smoking cessation, the lung cancer risk from smoking fades more slowly, with several studies showing that an ex-smoker who quit 10 to 15 years earlier is still several times more likely to die of lung cancer than someone who has never smoked (8). [...]there has been considerable effort over the past three decades to develop chemoprevention strategies, using dietary or pharmacological interventions to slow or reverse the progression to invasive lung cancer (10). Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Anil Vachani1, Lecia V. Sequist2, and Avrum Spira3 1Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; and 3Section of Computational Biomedicine, Department of Medicine, Boston University Medical Center, Boston, Massachusetts (Received in original form February 27, 2017; accepted in final form March 16,...
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201702-0433CI